Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium

BACKGROUND: In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most frequent cause of death from cancer in males (3.8%). Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of bladder c...

Descripción completa

Detalles Bibliográficos
Autores principales: Goossens, Maria E, Buntinx, Frank, Joniau, Steven, Ackaert, Koen, Ameye, Filip, Billiet, Ignace, Braeckman, Johan, Breugelmans, Alex, Darras, Jochen, Dilen, Kurt, Goeman, Lieven, Kellen, Eliane, Tombal, Bertrand, Van Bruwaene, Siska, Van Cleyenbreuge, Ben, Van der Aa, Frank, Vekemans, Kris, Van Poppel, Hendrik, Zeegers, Maurice P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352119/
https://www.ncbi.nlm.nih.gov/pubmed/22436453
http://dx.doi.org/10.1186/1471-2490-12-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352119/
https://www.ncbi.nlm.nih.gov/pubmed/22436453
http://dx.doi.org/10.1186/1471-2490-12-8

Ejemplares similares